|
1) Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009; 41: 591-5
|
|
|
|
2) Guo X, Zhang Y, Li J, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology. 2011; 53: 422-8
|
|
|
|
|
|
3) O'Brien TR, Kohaar I, Pfeiffer RM, et al. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver. Genes Immun. 2011(in press)
|
|
|
|
|
|
4) Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41: 1105-9
|
|
|
|
|
|
5) Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401
|
|
|
|
|
|
6) Stuppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41: 1100-4
|
|
|
|
|
|
7) Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461: 798-801
|
|
|
|
|
|
8) Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010; 139: 1586-92
|
|
|
|
|
|
9) Siren J, Pirhonen J, Julkunen I, et al. IFN-alpharegulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, IL-29. J Immunol. 2005; 174: 1032-7
|
|
|
|
|
|
10) Kawaoka T, Hayes CN, Ohishi W, et al. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotype 2a and 2b. J Hepatol. 2011; 54: 408-14
|
|
|
|
|
|
11) Sakamoto N, Nakagawa M, Tanaka Y, et al. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differ-ences between genotype 2a and 2b. I Med Virol. 2011; 83: 871-8
|
|
|
|
|
|
12) Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, detemied by a suitable genotyping method, is a better predictor for response to pegylated interferon-a/ribavirin therapy in Japanese patients than other SNPs associated with IL28B. J Clin Microbiol. 2011; 49: 1853-60
|
|
|
|
|
|
13) Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and geneteic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010; 52; 421-9
|
|
|
|
|
|
14) Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010; 139: 499-509
|
|
|
|
|
|
15) Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differentiatial expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010; 52: 1888-96
|
|
|
|
|
|
16) Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005; 128: 1437-44
|
|
|
|
|
|
17) Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008; 105: 7034-9
|
|
|
|
|
|
18) Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010; 464: 405-8
|
|
|
|
|
|
19) Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribaviirn-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010; 139: 1190-7
|
|
|
|
|
|
20) Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res. 2010; 40: 1063-70
|
|
|
|
|
21) Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology. 2011; 53: 415-21
|
|
|
|
|
|
22) Kumar V, Kato N, Urabe Y, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011; 43: 531-8
|
|
|
|
|
|
23) Jinushi M, Takehara T, Tatsumi T, et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol. 2005; 43: 1013-20
|
|
|
|
|